Skip to main content

Table 1 Prevalence of resistance to FQs antimicrobials in swine-derived E. coli isolates of different DANO MICs

From: The prevalence and mechanism of fluoroquinolone resistance in Escherichia coli isolated from swine farms in China

Antimicrobials DANO MIC (μg/mL) HLJ JL LN SD HN HB YN Resistance (%) Total
Norfloxacin ≥128 27/34 26/27 24/24   26/27 1/1 1/1 92.11% (105/114)  
64 13/16 11/14 11/11   10/10    88.24% (45/51)  
32 9/15 8/12 10/10 1/2 6/6    75.56% (34/45)  
16 1/10 1/10 1/10 7/10 3/10    26% (13/50)  
8a 0/7 0/6 2/7   0/7   0/2 6.9% (2/29)  
4–0.5 4/24 0/18 2/20 1/6 0/18 0/15 0/11 6.25% (7/112)  
≤0.25 0/20 0/17 0/14 0/3 0/18 0/4 0/2 0 (0/78) 43.00% (206/479)
Ciprofloxacin ≥128 28/34 26/27 24/24   26/27 1/1 1/1 92.98% (106/114)  
64 13/16 11/14 11/11   10/10    88.24% (45/51)  
32 10/15 8/12 10/10 1/2 6/6    77.78% (35/45)  
16 1/10 5/10 5/10 10/10 7/10    56% (28/50)  
8a 0/7 1/6 4/7   1/7   0/2 20.69% (6/29)  
4–0.5 4/24 1/18 2/20 1/6 0/18 0/15 0/11 7.14% (8/112)  
≤0.25 0/20 0/17 0/14 0/3 0/18 0/4 0/2 0 (0/78) 47.60% (228/479)
Ofloxacin ≥128 26/34 26/27 24/24   26/27 1/1 1/1 91.23% (104/114)  
64 12/16 12/14 10/11   10/10    86.27% (44/51)  
32 10/15 8/12 9/10 1/2 6/6    75.56% (34/45)  
16 1/10 3/10 4/10 10/10 7/10    50% (25/50)  
8a 0/7 1/6 3/7   3/7   0/2 24.14% (7/29)  
4–0.5 4/24 1/18 4/20 1/6 1/18 0/15 0/11 9.82% (11/112)  
≤0.25 0/20 0/17 0/14 0/3 0/18 0/4 0/2 0 (0/78) 47.00% (225/479)
Levofloxacin ≥128 24/34 25/27 23/24   26/27 1/1 1/1 87.72% (100/114)  
64 9/16 9/14 9/11   10/10    72.55% (37/51)  
32 3/15 7/12 4/10 1/2 5/6    44.44% (20/45)  
16 1/10 0/10 2/10 9/10 5/10    34% (17/50)  
8a 0/7 0/6 3/7   2/7   0/2 17.24% (5/29)  
4–0.5 4/24 0/18 2/20 1/6 0/18 0/15 0/11 6.25% (7/112)  
≤0.25 0/20 0/17 0/14 0/3 0/18 0/4 0/2 0 (0/78) 38.83% (186/479)
  1. Note: DANO Danofloxacin, HLJ Heilongjiang, JL Jilin, LN Liaoning, SD Shandong, HN Henan, HB Hubei, YN Yunan; a, the susceptibility breakpoint of DANO against swine-derived E. coli [5]